The biologics outsourcing market size has grown rapidly in recent years. It will grow from $20.06 billion in 2024 to $22.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing R&D costs, regulatory pressure, demand for specialized expertise, globalization
The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $37.52 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to emerging markets’ growth, personalized medicine, strategic alliances, biological drug patent expirations. Major trends in the forecast period include advancements in technology, increased outsourcing complexity, biosimilars market expansion, data analytics integration, supply chain resilience.
Get Your Free Sample of The Global Biologics Outsourcing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp
What key drivers have fueled the biologics outsourcing market’s development over the years?
The rising number of cancer cases is expected to propel the growth of the biologics outsourcing market going forward. Cancer is a broad category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Biologics outsourcing plays a significant role in cancer cases by providing specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies, including monoclonal antibodies, immunotherapies, and other targeted biologics that are used for the diagnosis, treatment, and management of various types of cancer. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, there were 1,958,310 new cancer cases in the United States, and 609,820 cancer deaths are projected to occur in 2023. Further, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million by 2040. Therefore, the rising number of cancer cases is driving the growth of the biologics outsourcing market.
What is the segmentation for the biologics outsourcing market?
The biologics outsourcing market covered in this report is segmented –
1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products
2) By Source: Human, Microbial, Other Source
3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications
4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)
Subsegments:
1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies
2) By Recombinant: Recombinant Proteins, Recombinant DNA Products
3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines
4) By Protein: Enzymes, Hormones, Cytokines
5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report
Who are the most influential companies in the biologics outsourcing market?
Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.
What are the top industry trends projected to impact the biologics outsourcing market?
Developments in biologics are a key trend gaining popularity in the biologics outsourcing market. Major companies operating in the biologics outsourcing market are adopting new technologies to sustain their position in the market. For instance, in February 2022, Abzena, a US-based contract development and manufacturing organization (CDMO), Alira Health, a US-based healthcare firm, and Oncodesign, a France-based biopharmaceutical company, launched DRIVE-Biologics, a consortium designed for biologic drug discovery and development programs. This provides integrated solutions with specialist services, from biological discovery to clinical and commercial manufacturing. This partnership, which combines industry leadership in fields such as design and developability, proof of concept in preclinical pharmacology and pharmaco-imaging, toxicology, and clinical design through commercial manufacturing, would streamline information sharing and program deliverables to help de-risk biologics development. Additionally, partners would have access to expertise at all drug discovery and development stages, including design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).
What are the major regional insights for the biologics outsourcing market, and which region holds the top position?
North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Biologics Outsourcing Market Report 2025 Offer?
The biologics outsourcing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Biologics outsourcing refers to pharmaceutical companies partnering with external vendors or contract manufacturing organizations (CMOs) to outsource various aspects of biologic drug development, manufacturing, and supply chain management. This is used in the pharmaceutical industry for different purposes related to biological drug development, manufacturing, and supply chain management.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12573
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
